Once‐daily vs twice‐daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial

DOI Web Site Web Site PubMed 1 Citations
  • Masayoshi Okumi
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Kohei Unagami
    Department of Nephrology Tokyo Women’s Medical University Tokyo Japan
  • Miyuki Furusawa
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Yoichi Kakuta
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Junpei IIzuka
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Toshio Takagi
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Hiroki Shirakawa
    Department of Urology Ohkubo Hospital Tokyo Japan
  • Tomokazu Shimizu
    Department of Urology and Transplant Surgery Toda Chuo General Hospital Saitama Japan
  • Kazuya Omoto
    Department of Urology and Transplant Surgery Toda Chuo General Hospital Saitama Japan
  • Masashi Inui
    Department of Urology, Yachiyo Medical Center Tokyo Women’s Medical University Chiba Japan
  • Hideki Ishida
    Department of Urology Tokyo Women’s Medical University Tokyo Japan
  • Kazunari Tanabe
    Department of Urology Tokyo Women’s Medical University Tokyo Japan

Search this article

Description

<jats:title>Abstract</jats:title><jats:p>Tacrolimus (TAC) is available as a twice‐daily capsule (TAC‐BID), once‐daily capsule (TAC‐QD), and once‐daily tablet. Recipients with ABO‐incompatible/anti‐human leukocyte antigen (HLA)‐incompatible transplantation were excluded in previous trials and have thus not been evaluated. We conducted a 5‐year trial to determine whether TAC‐QD is noninferior to TAC‐BID for transplant outcomes. Adults who underwent de novo living kidney transplantation were randomly assigned (62 TAC‐QD; 63 TAC‐BID). We did not exclude ABO‐/HLA‐ incompatible transplantation. TAC was initiated 7 days preoperatively (0.10 mg/kg/d). Mycophenolate mofetil, methylprednisolone, and basiliximab were administered. The primary endpoint was graft failure (non‐censored for death). We performed a noninferiority test. The noninferiority margin was 10% in risk difference. Five‐year graft failure rates were 6.5% and 9.5% for TAC‐QD and TAC‐BID, respectively (noninferiority, <jats:italic>P</jats:italic> = 0.009). The estimated glomerular filtration rates were similar between the groups (noninferiority, <jats:italic>P</jats:italic> < 0.001). TAC‐QD did not have point estimates of risk difference above the inferiority margin in any assessed endpoints. However, a tendency of interaction was observed between biopsy‐proven acute rejection and the follow‐up period. In a living kidney transplant population with 40% of patients with ABO/HLA incompatibility, the effect of TAC‐QD was not appreciably worse on various clinical transplant outcomes than that of TAC‐BID over 5 years.</jats:p>

Journal

Citations (1)*help

See more

Keywords

Report a problem

Back to top